Sunifiram

guinea pig

Also seen as: DM-235, DM235, suni

The Dose Guy’s verdict
Sep 1, 2026
3 sources

Sunifiram does something interesting in a dish, at doses so low they make other nootropics look crude. But zero human beings have ever been studied on it, for anything, and the entire evidence base is mouse behavior and rat brain slices. The community runs it anyway, and I get the appeal. Understand what you are buying: an experiment with you as the subject and no safety net underneath. If the AMPA mechanism is what draws you and you want human data behind it, TAK-653 is the one that reached clinical studies, though it is not broadly available either.

Would I take it?Caution, pure self-experiment.

What it is

A piperazine-derived research chemical out of an Italian university lab, structurally unrelated to the racetams despite landing on the same shelf. Sunifiram works through AMPA receptors and the glycine site on NMDA receptors, boosting long-term potentiation, the cellular process behind learning and memory. The potency in tissue work is striking, active in the low nanomolar range, but that is a dish, not a person. It also raises acetylcholine release from the cortex, giving it a cholinergic angle on top of the glutamatergic one.

On this shelf it sits next to its rarer cousin unifiram, same lab, same mechanism story, even less data. If the AMPA mechanism appeals and you want a version with actual clinical footing, TAK-653 is the compound that reached human trials.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

No human trial, no human pharmacokinetics, no human safety study. Everything below is rodent and tissue work.

In mouse hippocampal slices, sunifiram enhanced long-term potentiation at 10 to 100 nM with a bell-shaped response peaking at 10 nM, blocked by a glycine-site antagonist.Hippocampus 2013 · mouse slices
Sunifiram prevented scopolamine-induced amnesia in mouse passive avoidance at 0.001 to 0.1 mg/kg i.p. and 0.01 to 0.1 mg/kg orally, without impairing motor coordination.Naunyn-Schmiedeberg's 2002 · mouse behavior
A 2022 paper on sunifiram carbamate hybrids was retracted. The retraction hits a derivative paper, not the core sunifiram data, but it thins an already small literature.J Enzyme Inhib Med Chem 2026 · retraction
No human study of sunifiram exists in PubMed. No human safety, tolerability, or pharmacokinetic data of any kind.as of Aug 2026

Realistic protocols

I am not building a protocol table for a compound with zero human data. The community runs sunifiram sublingually, held under the tongue, because oral bioavailability in a person has never been measured and the forum consensus is that sublingual hits harder and faster. Doses are tiny: 5 to 10 mg is the common range, and the effect kicks in within 15 to 30 minutes. Most people use it acutely, on study or work days, rather than running a continuous cycle. Dose late and you will not sleep. Stacking it with caffeine or other stimulants amplifies the jittery edge. Do not combine with other glutamatergic compounds.

Nobody has established a safe dose in a human, so everything here is what people actually run, not what anyone has proven is fine. Sublingual, 5 to 10 mg, on demand. Go low, keep runs short, log what you take and what you notice. You are the study.

Side effects

Zero human safety data, so this is all anecdote:

anecdotalStimulant edge, restlessness, or a jittery feeling, dose-dependent. The glutamatergic push.
anecdotalHeadache, especially in the first few uses or at higher doses. Some users pair it with a choline source and report it helps.
anecdotalInsomnia if dosed late. The activation window is short but sharp.
unknownNo human has ever been studied on this compound. No toxicology, no organ-safety panel, no long-term data. You are the trial.

Where to buy

$59.99 / unit
⚠ ⚠ Unreachable since Sep 11
✓ verified Sep 8

Prices move. Links are affiliate links; they never change a ranking, and scores are set before the deal exists.